Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | completed | Phase 1 | 79 | Incendia TherapeuticsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT05017025 | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | completed | Phase 1 / Phase 2 | 61 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06863233 | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05241834 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | completed | Phase 1 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00720785 | Natural Killer Cells and Bortezomib to Treat Cancer | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01167530 | Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer(RAD001) | completed | Phase 1 | 26 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04858958 | Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation(FAVOUR) | completed | Phase 1 | 90 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06532032 | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer(swalloWTail) | completed | Phase 1 / Phase 2 | 12 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 31, 2026 | clinicaltrials |
| NCT02718066 | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 96 | HUYABIO International, LLC.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03581487 | Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT04919369 | All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 | 18 | Dwight OwenOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03383302 | SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects(STILE) | completed | Phase 1 / Phase 2 | 36 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | completed | Phase 1 | 145 | Coherus Oncology, Inc.INDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06403436 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors(TT-CSP-001) | completed | Phase 1 | 45 | TOLREMO therapeutics AGINDUSTRY | 3 | Jul 7, 2026 | clinicaltrials |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients(RAMP204) | completed | Phase 1 / Phase 2 | 12 | Verastem, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT01642251 | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 156 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04181788 | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies | completed | Phase 1 / Phase 2 | 155 | PfizerINDUSTRY | 6 | Jun 15, 2026 | clinicaltrials |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 | 273 | Genentech, Inc.INDUSTRY | 8 | Jun 8, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03758287 | Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | completed | Phase 1 / Phase 2 | 108 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT01625234 | Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 131 | Xcovery Holdings, Inc.INDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT01802632 | AZD9291 First Time In Patients Ascending Dose Study(AURA) | completed | Phase 1 / Phase 2 | 603 | AstraZenecaINDUSTRY | 10 | Apr 20, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04479306 | Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01118676 | Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer | completed | Phase 1 | 14 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03678350 | Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06525246 | Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer | completed | Phase 1 | 78 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT02858869 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | completed | Phase 1 | 25 | Emory UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04900363 | A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC | completed | Phase 1 / Phase 2 | 108 | AkesoINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02523469 | ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 67 | Medical University of South CarolinaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06575933 | A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04384146 | Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials